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ABSTRACT
Background Of the estimated 10 million people affected 
by (TB) each year, one- third are never diagnosed. Delayed 
case detection within the private healthcare sector has 
been identified as a particular problem in some settings, 
leading to considerable morbidity, mortality and community 
transmission. Using unannounced standardised patient 
(SP) visits to the pharmacies, we aimed to evaluate the 
performance of private pharmacies in the detection and 
treatment of TB.
Methods A cross- sectional study was undertaken at 
randomly selected private pharmacies within 40 districts 
of Vietnam. Trained actors implemented two standardised 
clinical scenarios of presumptive TB and presumptive 
multidrug- resistant TB (MDR- TB). Outcomes were the 
proportion of SPs referred for medical assessment and 
the proportion inappropriately receiving broad- spectrum 
antibiotics. Logistic regression evaluated predictors of SPs’ 
referral.
Results In total, 638 SP encounters were conducted, 
of which only 155 (24.3%) were referred for medical 
assessment; 511 (80·1%) were inappropriately offered 
antibiotics. A higher proportion of SPs were referred 
without having been given antibiotics if they had 
presumptive MDR- TB (68/320, 21.3%) versus presumptive 
TB (17/318, 5.3%; adjusted OR=4.8, 95% CI 2.9 to 7.8). 
Pharmacies offered antibiotics without a prescription 
to 89.9% of SPs with presumptive TB and 70.3% with 
presumptive MDR- TB, with no clear follow- up plan.
Conclusions Few SPs with presumptive TB were 
appropriately referred for medical assessment by private 
pharmacies. Interventions to improve appropriate TB 
referral within the private pharmacy sector are urgently 
required to reduce the number of undiagnosed TB cases in 
Vietnam and similar high- prevalence settings.
BACKGROUND
Tuberculosis (TB) is a leading infectious 
cause of death globally, and TB case numbers 
are estimated to increase even further due 
to the disruptions caused by the COVID- 19 
pandemic.1 An estimated 10 million people 
developed TB globally in 2019, of whom 
approximately one- third were never detected 
or offered appropriate treatment.1 This 
Key questions
What is already known?
 ► Tuberculosis (TB) is a leading infectious disease 
killer globally; control efforts are undermined by 
inadequate case detection and delayed diagnoses, 
particularly in private settings in countries with a 
high incidence of TB.
 ► Patients with potential TB frequently approach pri-
vate pharmacies to access care in these TB high- 
incidence settings; they are often not referred for TB 
screening and are supplied a short- term course of 
broad- spectrum antibiotics, which lead to delayed 
case detection and enable ongoing community 
transmission.
 ► There was no geographically representative ev-
idence estimating the magnitude of the problem 
regarding presumptive TB patient referrals and an-
tibiotic supply within the private pharmacy sector in 
Vietnam, which responds to two- thirds of the popu-
lation’s healthcare needs.
What are the new findings?
 ► Our multicentre study, using a standardised patient 
method, provides estimates of pharmacy referral 
practices for patients with presumptive TB in the 
northern and southern regions of Vietnam.
 ► Private pharmacies frequently fail to recognise TB 
symptoms or to refer patients to TB services, con-
tributing to low rates of case detection; many pa-
tients with presumptive TB were inappropriately 
given antibiotics, including fluoroquinolones.
 ► These findings add to the growing evidence in the 
literature on limited contribution of private pharma-
cies to TB case finding and the appropriate use of 
antibiotics in community settings.
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persistent case- detection gap comprises around 2.9 
million cases each year and results in continuing commu-
nity transmission and undermining national and global 
TB control efforts.2
Studies from high- incidence settings have shown that 
patients with TB frequently experience significant delays 
before obtaining a diagnosis.3 The accessibility and 
trusted role of pharmacies in local communities4 mean 
that patients frequently attend private pharmacies soon 
after developing symptoms of TB.5–7 In India, Vietnam 
and Uganda, between 40% and 60% of patients who 
were ultimately diagnosed with TB visited a private phar-
macy prior to medical assessment and TB diagnosis.3 8 9 
Although private pharmacies should play an important 
role in case detection and referral, inappropriate 
management often contributes to delayed diagnosis and 
TB- specific treatment. Pharmacies may also contribute 
to the development of antimicrobial resistance (AMR) if 
they dispense inadequate broad- spectrum antibiotics to 
patients with TB.10 Hence, private pharmacies have been 
identified as important stakeholders in both TB and 
AMR control efforts.6
Private sector engagement is a top priority of the WHO, 
which encourages national TB control programmes 
to develop strong public–private partnerships as a part 
of their End TB Strategy.11 The private sector plays an 
important role in Vietnam1 and in other middle- income 
countries in Southeast Asia with a high incidence of TB 
and drug- resistant TB.1 In Vietnam, private pharmacies 
account for two- thirds of health service encounters.12 A 
previous study has shown that a minority of patients in 
northern Vietnam were referred by private pharmacies to 
a medical facility capable of establishing a TB diagnosis.13
We aimed to evaluate the referral practices of private 
pharmacies in Vietnam for standardised patients (SPs) 
presenting with symptoms of presumptive TB and drug- 
resistant TB as unannounced ‘mystery shoppers’.
METHODS
Study design and setting
A cross- sectional study was undertaken from April to 
November 2019 using an SP study method, with SPs 
visiting randomly selected private pharmacies in 40 
districts of Vietnam. This included urban and rural areas 
in the northern (Hanoi and Thanh Hoa) and southern 
(Ca Mau and An Giang) provinces (figure 1). Vietnam is 
a middle- income country in Southeast Asia with a high 
incidence of TB (176/100 000) and multidrug- resistant 
TB (MDR- TB) (8.8/100 000) (defined as TB that is 
resistant to the two most effective first- line antibiotics, 
rifampicin and isoniazid).1 Tuberculosis diagnosis and 
treatment in Vietnam are largely provided by a public 
National Tuberculosis Program. However, the private 
pharmacy sector has expanded rapidly over the past two 
decades and is the first point of healthcare contact for 
the majority of patients.12
The SP study is regarded as a proven and widely used 
methodological tool for pharmacy practice research.14 15
Sampling
Districts located within 2 hours’ drive or less than 150 
km from the provincial centre were included. Within 
each district, a geographical area comprising approxi-
mately one- quarter of the total population was selected 
by convenience sampling. The Global Positioning System 
location of private pharmacies in the selected geograph-
ical area was established by the research team physi-
cally walking the streets and identifying all pharmacies. 
Pharmacies were classified as either private pharmacies 
or drug counters. Vietnamese regulations stipulate that 
‘private pharmacies’ in urban areas must be managed 
by a university graduate pharmacist, and ‘drug counters’ 
must be led by a pharmacist with college certification.16 
Counters selling only traditional medicines, wholesalers 
and pharmacies located within government health facili-
ties or private hospitals were excluded. Throughout this 
article, the term pharmacy refers to both drug counters 
and private pharmacies. Pharmacies were classified as 
registered (registration identification (ID) displayed on 
the signboard of the pharmacy) or unregistered (no ID 
displayed).
A total of 1643 eligible private pharmacies were iden-
tified during the mapping process. Details of the study 
site selection process are included in the online supple-
mental material.
Figure 1 Provinces and districts selected for study 
participation.
Key questions
What do the new findings imply?
 ► Our results demonstrate the need to improve the skills of pharmacy 
staff in the early recognition and appropriate referral of patients 
with possible TB.
 ► The study highlights the importance of improving antimicrobi-
al stewardship in the community pharmacy setting and supports 
the WHO’s important recommendations for public–private mix ap-
proaches to strengthen TB case finding.
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Development of clinical scenarios
Two clinical scenarios were developed in collaboration 
with clinicians, pharmacists, public health experts and 
researchers from Vietnam and Australia:
Presumptive TB: the first scenario involved a male adult 
with the following symptoms: cough for 3 weeks, fever, 
loss of appetite and weight loss, as well as reporting 
a history of using cough medication without any im-
provement. The patient had not previously sought or 
received testing for TB.
Presumptive MDR- TB: the second scenario comprised a 
patient with a cough of 4- week duration and a history 
of previous TB treatment, with early treatment inter-
ruption. The scenarios are summarised in table 1.
These two scenarios reflect typical clinical presenta-
tions with TB. Scenarios used in other settings17 18 were 
localised to the Vietnamese context, in consultation with 
clinical pharmacy lecturers, community pharmacists and 
other clinicians. The scenarios were piloted in 14 phar-
macies in northern and southern regions, with further 
refinement prior to implementation.
For both scenarios, the research design included only 
middle- aged men as SPs because 75% of prevalent TB 
cases in Vietnam are male.19 Local actors were trained to 
present as an SP for one of the two scenarios over a 4- day 
period by a researcher with experience implementing 
SP studies in other settings. Training included initial 
briefing, interactive discussions, role plays and pilot visits 
to private pharmacies. Actors were evaluated against 
a checklist to ensure a convincing and standardised 
performance.
SP visits
A sample of 636 pharmacies were allocated to each of 
the four provinces according to proportionate to the 
provincial sample of the eligible mapped pharmacies. 
A systematic sampling technique was used to select the 
pharmacies for each scenario. The fifth and sixth phar-
macies were selected, starting from a random point of the 
list of eligible pharmacies in each province for presump-
tive TB and presumptive MDR- TB scenarios, respectively, 
until the provincial quota was filled. The same process 
was continued in all four provinces to randomly allo-
cate pharmacies to both scenarios. The trained SPs were 
randomly assigned to pharmacies using a predetermined 
randomisation protocol.
Each selected pharmacy was visited during business 
hours by one SP and one observer. The observer was 
identified as a friend and listened to the interaction but 
did not participate in the clinical encounter. Immediately 
after leaving the pharmacy, the SP and observer jointly 
documented the outcome of the visit by completing a 
structured data collection sheet. They also collected an 
audio recording of their visit for narrative analysis. The 
recording mentioned the number of customers present 
in the shop, the number of staff present, the behaviour 
of the staff and the layout of the pharmacy.
Table 1 Overview of SP scenarios
Scenario description Presenting history Expected outcome
1. Presumptive TB: 2–3 weeks of cough 
with intermittent fever, along with loss of 
appetite and weight loss;
seeking medical advice for the first time.
‘I have a cough and fever for the last 2–3 
weeks that is not getting better. I have 
lost my appetite and feel I am losing 
weight. I have taken cough medicine but 
there is no improvement. Can I get some 
medicines?’
Verbal or written referral to a doctor in 
a TB centre, hospital or a healthcare 
provider without dispensing any 
antibiotics.
2. Presumptive MDR- TB: 4 weeks of 
cough with history of incomplete TB 
treatment, seeking medical advice for the 
first time.
‘I have been suffering from a bad cough 
for about 4 weeks. I took some traditional 
medicines for cough relief, but they are 
not working. It seems to be similar to 
the cough I had 2 years ago when I got 
TB. But I remember that I was already 
treated for TB for 3 months and the tests 
were fine. Is it related to my previous 
condition? What do you suggest?’
The SPs would admit to a loss of 
appetite, to his clothes becoming a 
bit loose, fever and feeling fatigued if 
prompted by the pharmacy staff. If the 
staff asked about history of TB treatment, 
the SPs would say ‘I did it for about 3 
months, later, when the doctor found my 
sputum test was fine, I thought it was 
cured and after 3 months of treatment, I 
stopped taking the medication’.
Verbal or written referral to a doctor in 
a TB centre, hospital or a healthcare 
provider without dispensing any 
antibiotics.
MDR- TB, multidrug- resistant tuberculosis; SP, standardised patient; TB, tuberculosis.
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Stepped antibiotic request
During each encounter, we assessed the pharmacy staff 
member’s willingness to supply antibiotics at three levels 
of increasing consumer demand.14 20 During the initial 
consultation, SPs asked for an unspecified medicine to 
alleviate their symptoms, without specifying an antibiotic 
(a ‘level 1’ request). If an antibiotic was not provided 
during the initial interaction, they asked for a stronger 
medicine: ‘can you give me any stronger medicine?’ 
(level 2 request). If the pharmacy staff did not provide an 
antibiotic, they then explicitly requested an antibiotic: ‘I 
want an antibiotic’ (level 3 request).
Medicines supplied by the pharmacy were identified 
by a team of three study pharmacists and were coded 
according to their therapeutic mode of action. Anti-
biotics were classified according to their generic name 
and grouped into three major categories: (1) fluoro-
quinolones; (2) non- fluoroquinolone broad- spectrum 
antibiotics (antibiotics that are effective against both 
Gram- positive and Gram- negative bacteria, including 
cephalosporins, broad- spectrum penicillins, sulfon-
amides, macrolides and tetracyclines); and (3) other 
antibiotics. We classified steroids and non- steroidal anti- 
inflammatory drugs as anti- inflammatory.
We assessed antibiotic supply in two ways: (1) ‘antibi-
otic offered’, which was reported in the data collection 
sheet by the SP and the observer (without medical knowl-
edge) based on the interaction with pharmacy staff; 
and (2) ‘actual antibiotic supplied’, which was recorded 
after verification of the received antibiotics by the study 
pharmacists.
Outcome measures
The primary outcome for both clinical scenarios was the 
proportion of ‘SPs’ who were referred for medical assess-
ment. This referral includes to TB clinics, public hospi-
tals and private clinics. Secondary outcomes included the 
proportion of SPs referred without antibiotic supply, the 
proportion pharmacy staff who asked for additional infor-
mation about medical history and medicines supplied 
(online supplemental material describes predesigned list 
of additional information related questions).
Data collection and analysis
Data collection
Data were documented on paper data collection forms 
immediately after a pharmacy visit and were later entered 
into an electronic Research Electronic Data Capture 
(REDCap) database designed without having any phar-
macy identifiable information.21
Sample size
The sample size was based on an expected proportion 
of inappropriate antibiotic dispensing of 50%, based 
on studies from comparable settings.17 22 In order to 
ascertain the proportion of patients referred without 
supplying an antibiotic, with a precision of ±5% and an 
alpha of 0.05 (ie, 95% confidence limits), assuming half 
of the clusters were urban, we estimated that we needed 
a sample of 318 pharmacies for each scenario. This esti-
mation was derived using sample size formula for propor-
tions.23 Pharmacies were selected for each scenario from 
the eligible pharmacies using simple random sampling 
technique (online supplemental material).
Statistical analysis
Descriptive statistics evaluated pharmacy character-
istics (classification of pharmacy, registration status, 
geographical area and gender of the pharmacy staff), 
duration of interaction, population density, pharmacy 
density, the medical history taken by pharmacy staff, 
medications supplied and referral practices. Logistic 
regression was used to evaluate the relationship between 
these independent variables and the primary outcome 
measures. The comparative analysis employed multivar-
iable regression with backward elimination (SPSS V.24). 
Adjusted ORs (aORs) with 95% CIs were reported. The 
χ2 likelihood ratio test, pseudo R2 values and the Hosmer- 
Lemeshow χ2 test were used as model fit statistics to eval-
uate the multiple logistic regression models.
Patient and public involvement
This SP study was designed to assess presumptive TB 
patient referrals and medication supply at community 
pharmacies. Therefore, study participants were phar-
macy staff; patients or the public were not involved in the 
design, conduct, reporting or dissemination plans of our 
research.
RESULTS
Standardised patients visited 638 pharmacies, including 
318 with presumptive TB and 320 presumptive MDR- 
TB. Characteristics of selected pharmacies are shown in 
table 2. A greater proportion of pharmacies were classi-
fied as drug counters (89.3%) than private pharmacies 
(10.7%). About 60% of the pharmacies displayed their 
registration status externally.
Among 318 SPs presenting with presumptive TB, 39 
(12.3%, 95% CI 8.9% to 16.4%) encounters resulted in 
a referral to a healthcare provider (primary outcome). 
Among 320 SPs with presumptive MDR- TB, 116 (36.3%, 
95% CI 31.0% to 41.8%) encounters resulted in a referral 
to a healthcare provider (primary outcome). Only 17 
SPs (5.3%, 95% CI 3.1% to 8.4%) with presumptive TB 
and 68 (21.1%, 95% CI 16.9% to 26.1%) with presump-
tive MDR- TB were referred to healthcare providers 
without the provision of any antibiotics. Antibiotics were 
mostly offered without pressure (level 1 request) for the 
presumptive TB scenario by 92.3% of pharmacies, and 
for presumptive MDR- TB by 96.9% of pharmacies as 
compared with level 2 and level 3 requests (<8%).
Table 3 presents factors associated with referral for 
medical assessment. Pharmacies in the south were more 
likely to refer the SPs to healthcare providers than their 
northern counterparts for presumptive TB (aOR=8.8, 
95% CI: 3.8 to 20.4) and presumptive MDR- TB (aOR=4.8, 
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95% CI 2.9 to 7.8), respectively. A significantly higher 
proportion of pharmacy staff inquired about the medical 
history of patients, during interactions with SPs who had 
presumptive MDR- TB (n=245, 76.6%), in comparison to 
those who had presumptive TB (n=195, 61.3%).
Pharmacy staff who asked about SPs’ medical history 
were more likely to refer them to healthcare providers, 
for both the presumptive TB (aOR=3.9, 95% CI 1.7 to 
9.0) and MDR- TB (aOR=1.7, 95% CI 0.9 to 3.3) scenarios. 
There was no association between the duration of the 
SPs’ encounter and the proportion of SPs referred for 
medical assessment.
Table 4 shows the categories of medicines supplied by 
pharmacy staff. A total of 1475 individual medicines were 
supplied during the presumptive TB encounters (median 
five drugs, IQR 4–6 drugs) and 1128 different medicines 
during the presumptive MDR- TB encounters (median 
four drugs, IQR 0–5 drugs). Over a quarter of medicines 
were unlabelled. Antibiotics were the most common cate-
gory of medicines offered to SPs with presumptive TB 
(286/318; 89.9%, 95% CI 86.1% to 93.0%) and presump-
tive MDR- TB (225/320; 70.3%, 95% CI 65.0% to 75.3%).
Antibiotics dispensed
Among the antibiotics verified by study pharmacists 
(n=258) during the presumptive TB encounters, 202 
(78.3%) were broad- spectrum non- fluoroquinolone 
antibiotics (cephalosporins, broad- spectrum penicil-
lins, macrolides, sulfonamides or tetracyclines) and 45 
(17.4%) of antibiotics were fluoroquinolones. Medi-
cations used as part of standardised regimens to treat 
TB, such as levofloxacin or rifampicin, were supplied 
to 14 (5.4%) SPs with presumptive TB encounters and 
33 (13.7%) SPs presenting with presumptive MDR- TB. 
No SPs were provided with a recommended treatment 
regimen for TB. More than one antibiotic was supplied in 
16 (6.2%) and 39 (16.2%) encounters involving SPs with 
presumptive TB and presumptive MDR- TB, respectively.
Other common classes of medicines supplied to SPs 
were antitussives (16.8%), and combination cough and 
cold formulations (including two or more of antitussives, 
antihistamines and/or analgesics, 8.9%; table 4).
DISCUSSION
This SP study involving 638 pharmacies across Vietnam is 
the largest and most geographically representative study 
of its kind conducted in Vietnam to date. It demonstrated 
that only a small proportion of SPs with symptoms of 
presumptive TB and presumptive MDR- TB were referred 
for medical assessment. Pharmacists taking a medical 
history were more likely to make a referral than those 
who did not take a history. Broad- spectrum antibiotics, 
including fluoroquinolones, were commonly supplied to 
SPs.
The low proportion of referrals for medical assess-
ment demonstrates the missed opportunities for early 
case- finding through pharmacies. Delays in accessing 
testing and treatment for TB undermine control efforts 
as patients may remain contagious for prolonged periods 
prior to diagnosis, increasing transmission of Mycobac-
terium tuberculosis in the community. Delayed diagnosis 
has been shown to increase TB- related morbidity and 
mortality.24
Our findings are consistent with studies using SPs in 
India and a self- reported study among pharmacy staff in 
Cambodia.17 25 In India, only 13.0% of the patients with 
presumptive TB symptoms and 62.0% of patients with 
confirmed TB were referred to a healthcare provider,17 
whereas in Cambodia, 29.6% patients were referred for 
appropriate TB treatment.25 Our study found a lower 
proportion of referral across Vietnam than a study of 
138 private pharmacies in an urban Hanoi province of 
Vietnam, in which 46.0% of patients were referred.13 
In this prior study, 20 pharmacies located within 500 m 
distance from two TB hospitals were purposely selected 
and SPs specifically requested TB medications, poten-
tially leading to more referrals. A cross- sectional study 












  Pharmacy 30 (1.6) 38 (11.9)
  Drug counter 288 (90.6) 282 (88.1)
Pharmacy registration status
  Not registered 129 (40.6) 128 (40.0)
  Registered 189 (59.4) 192 (60.0)
Region
  North 200 (62.9) 201 (62.8)
  South 118 (37.1) 119 (37.2)
Geographical area
  Rural 273 (85.8) 275 (85.9)
  Urban 45 (14.2) 45 (14.1)
Gender of pharmacy staff attending the SP
  Male 73 (23.0) 65 (20.3)
  Female 245 (77.0) 255 (79.7)
Duration of interaction (min)
  Median (IQR) 4 (3–5) 5 (4–5)
  Missing data 1
Commune population density (PPH)
  Median (IQR) 12 (8–16) 12 (8–17)
Number of pharmacies /10 000 population
  Median (IQR) 11 (7–17) 11 (7–17)
MDR- TB, multidrug- resistant tuberculosis; PPH, number of people 
per hectare; SP, standardised patient; TB, tuberculosis.
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Table 4 Pharmacy responses to SPs
Total SP scenarios
Presumptive TB MDR- TB
Frequency/proportion (%) Frequency/proportion (%)
N=318 N=320
Medical history taken*
  No 123 (38.7) 75 (23.4)
  Yes 195 (61.3) 245 (76.6)
Referral to medical facility
  Total referrals (any of the following) 39 (12.3) 116 (36.3)
  To TB centre 07 (2.2) 57 (17.8)
  To private clinic 12 (3.8) 28 (8.8)
  To district healthcare centre/hospital 31 (9.7) 46       (14.4)
  Referral without giving antibiotics (subgroup of all aforementioned 
referrals)
17 (5.3) 68 (21.3)
Number of ‘all medications’ dispensed
  Median (IQR) 5 (4–6) 4 (0–5)
  0 (no other medicine dispensed) 24 (7.5) 86 (26.9)
  1 2 (0.6) 1 (0.3)
  2 2 (0.6) 4 (1.3)
  3 30 (9.4) 23 (7.2)
  4 66 (20.8) 64 (20.0)
  5 105 (33.0) 83 (25.9)
  ≥6 89 (27.9) 59 (18.4)
Categories of medicines dispensed
  Number different types of medicines received in total 1475 (100) 1127 (100)
  Unlabelled medicines 436 (29.6) 311 (27.6)
  Antibiotics (general) 244 (16.5) 217 (19.3)
  Antibiotics (with anti- TB activity) 14 (0.9) 24 (2.1)
  Cough medicine 230 (15.6) 207 (18.4)
  Steroids/NSAIDS (anti- inflammatory) 113 (7.7) 107 (9.5)
  Antihistamines 64 (4.3) 51 (4.5)
  Pain/fever relief 46 (3.1) 16 (1.4)
  Vitamin supplementary 70 (4.7) 32 (2.8)
  Other identified medicine (bronchodilators, proton- pump inhibitors, etc) 106 (7.2) 81 (7.2)
  Any combined formulation (combination of cough and cold formulations 
that included antitussives, antihistamines and/or analgesics)
152 (10.3) 81 (7.2)
Class of antibiotic dispensed† N=258 N=241
  Fluoroquinolones 45 (17.4) 39 (16.2)
  Broad- spectrum antibiotics other than fluoroquinolones 202 (78.3) 190 (78.8)
  Other antibiotic (includes lincomycins and unknown) 11 (4.3) 12 (5.0)
  Number of pharmacies sold one antibiotic 238 (92.2) 196 (78.7)
  Number of pharmacies sold two antibiotics 20 (7.8) 45 (18.7)
Prescription for an antibiotic requested by pharmacy staff
  No 312 (98.1) 212 (97.5)
  Yes 6 (1.9) 8 (2.5)
Antibiotic offered‡
  No 32 (10.1) 95 (29.7)
  Yes 286 (89.9) 225 (70.3)
Level of demand required to obtain antibiotic N=286 N=225
  Level 1 (Can I get some medicine to alleviate the symptoms?)
Continued
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among patients with diagnosed TB in southern Vietnam 
found that those who visited a pharmacy prior to their 
diagnosis were five times more likely to have delayed 
access to care (which was defined as more than 4 weeks 
from first noticed symptom to first health provider 
contact), compared with those who consulted a national 
TB programme facility first.26
A higher proportion of referrals in the MDR- TB 
scenario were expected, as reported previous history 
of TB refrained from any differential diagnosis and 
supported by previous studies,13 17 only about one quar-
ters of the pharmacies referred these SPs for screening. 
This poor referral suggests the pharmacy staff’s confu-
sion or lack of knowledge in identifying presumptive 
MDR- TB cases. Educating pharmacy staff on TB- related 
symptoms and importance of presumptive TB case refer-
rals might help to improve the early referrals for patients 
with presumptive TB.
There was significant regional variation in the referral 
patterns of pharmacies, with a greater referral rate in 
southern Vietnam. This shows a heterogeneity in private 
pharmacy practice between the regions, possibly due to 
various factors including, but not limited to, extent of 
pharmacy education and clinical training, business model 
and the culture that may contribute to this behaviour. 
This finding highlights the importance of undertaking 
studies in a wide range of settings in order to characterise 
differences in local practice and get a more comprehen-
sive overview. Nevertheless, low case referrals were the 
norm in all settings, which indicates that further effort is 
required to enhance cooperation between the public and 
private sectors across the country.
Our study showed a high proportion of encounters 
which resulted in the supply of broad- spectrum anti-
biotics to SPs, including antibiotics used in TB treat-
ment, particularly the fluoroquinolones (>16%) used 
in MDR- TB treatment. This is consistent with studies in 
other settings.17 27 These findings underpin concerns 
that unregulated dispensing of antibiotics is likely to 
amplify the risk of acquired drug resistance, especially 
against key second- line drugs.28 Inappropriate use of 
fluoroquinolones may also delay TB diagnosis due to 
a partial therapeutic effect that may improve patients’ 
symptoms and reduce the yield of microbiological tests 
for M. tuberculosis.29 Fluoroquinolones given to patients 
with undiagnosed MDR- TB compromise one of the most 
effective second- line TB drugs and will contribute to 
the emergence and spread of extensively drug- resistant 
TB.30 Antibiotics were dispensed predominantly at level 
1 request. Similar findings were also observed in SP 
studies conducted at private pharmacies in Sri Lanka14 
and Eritrea,31 where most antibiotics were spontaneously 
dispensed without any pressure exerted by SPs. There-
fore, we hypothesise that the current inappropriate anti-
biotic dispensing practice may be reflect profit motive 
than external patient pressure. A previous study in 
Vietnam also found that the revenue of selling antibiotics 
without a prescription is greater than all sales in both 
rural and urban pharmacies.32 As we also found that over 
95% of the sold antibiotics were broad- spectrum antibi-
otics, which are generally more expensive than narrow- 
spectrum antibiotics.
Our study has important public health implications by 
demonstrating a major opportunity to close persistent 
case- detection gaps if the private pharmacy sector can 
be better engaged. Our results demonstrate a need 
for interventions to improve the early recognition and 
appropriate referral of patients with presumptive TB 
(including MDR- TB) to public TB services. Training 
for pharmacy staff that improves their TB knowledge 
and emphasises the importance of history taking should 
improve the rate of referral. Doing this in a sustainable 
fashion may require inclusion in training curricula and 
better oversight/monitoring mechanisms. Support for 
effective public–private mix approaches, which have 
been advocated by the WHO and other international 
Total SP scenarios
Presumptive TB MDR- TB
Frequency/proportion (%) Frequency/proportion (%)
N=318 N=320
   Antibiotic given 264 (92.3) 218 (96.9)
   Antibiotic not given 13 (7.7) 7 (3.1)
  Level 2 (Can I get something stronger?)
   Antibiotic given 13 (4.5) 3 (1.3)
   Antibiotic not given 9 (3.1) 4 (1.8)
  Level 3 (I would like an antibiotic.)
   Antibiotic given 9 (3.1) 4 (1.8)
   Antibiotic not given 0 0
*Possible history taken by staff in relation to reported symptoms.
†Actual antibiotics received after being verified by study pharmacists.
‡Reported by standardised patient prior to verification by study pharmacists but not necessarily bought by SP due to several reasons (eg, no 
change cash notes available, told that antibiotics was dispensed but could not find these and vice versa, etc).
MDR- TB, multidrug- resistant tuberculosis; NSAID, non- steroidal anti- inflammatory drug; SP, standardised patient; TB, tuberculosis.
Table 4 Continued
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agencies, promise to make an important contribution to 
timely TB notification.33
The study also highlights the importance of improving 
antimicrobial stewardship (AMS) in general, especially in 
community settings where this is often neglected. AMS 
programmes promote the responsible use of antimicro-
bials through the delivery of evidence- based interventions 
but are often restricted to hospital settings.34 Although 
the programmes are highly regarded and considered 
essential to combat inappropriate antimicrobial use and 
protect human health in the long run,35 they are rarely 
implemented outside the hospital setting or with involve-
ment of community pharmacies. This remains a major 
challenge requiring better solutions, especially in settings 
like Vietnam, where the vast majority of antibiotics are 
dispensed at the community level.
Our study has a number of strengths. First, the use of 
standardised patients provides an accurate assessment of 
the actual behaviour of pharmacy staff. This avoids social 
desirability bias and observer bias (the Hawthorne effect), 
which are difficult to avoid with self- reported methods. 
The selection of actors from local communities increased 
authenticity and reduced the risk of detection. Second, 
our study population was broadly representative of the 
situation in both northern and southern Vietnam. We 
randomly selected pharmacies for each scenario across 
40 districts in the north and south of Vietnam, which 
adequately captured the diversity of practice across the 
study region.
Study limitations include the fact that the use of 
different actors may have introduced some variation in 
the scenarios. We reduced this by using a rigorous stan-
dardised training procedure with ongoing quality assess-
ment through the presence of an observer and external 
monitoring. SP studies conducted in India found that 
the personal characteristics of SPs had little effect on the 
quality of care provided by staff.36 We included popula-
tions located within 2 hours of major urban centres in 
the north and south of the country. These were repre-
sentative of urban and semirural populations in the most 
populous northern and southern regions of Vietnam. 
Remote rural populations were not examined in this 
study, for practical reasons. Our SPs had a restricted 
number of responses in order to improve standardisation 
across the study, although they were trained to commu-
nicate as naturally as possible. Responses were scripted 
using previous experience in conducting similar studies 
in other settings. While this study explored the practices 
of pharmacy staff, it did not assess the factors associated 
with pharmacists’ decisions to refer patients or provide 
antibiotics. This is an important area for future research, 
to enable interventions that will improve referral prac-
tices in the private pharmacy sector.
In conclusion, this study revealed that a low proportion 
of private pharmacies in Vietnam appropriately referred 
patients with presumptive TB for medical assessment. 
This is important to address, given the considerable TB 
case- detection gap observed in Vietnam,19 and highlights 
the importance of strengthening partnerships between 
the private and public sectors in order to achieve the 
WHO End TB targets. It also emphasises the need to 
involve community pharmacies in AMS initiatives in 
order to reduce the inappropriate use of broad- spectrum 
antibiotics in Vietnam.
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